secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0001104659-22-058543
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma Q1 net loss $2.7M ($0.26/shr); Phase 2b CDI trial progressing
--------------------------------------------------------------------------

- Cash $11.1M at March 31, 2022, down from $13.0M at Dec 31, 2021.
- Net loss $2.7M vs $1.5M YoY; R&D costs rose to $0.8M from $0.1M on Phase 2b trial costs.
- Phase 2b CDI trial enrollment ongoing; completion expected late H2 2022.
- Protocol amended to add exploratory Extended Clinical Cure endpoint at day 56 and day 84.
- Shares outstanding 10,263,202 as of March 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/0001104659-22-058543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922058543/tm2214543d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-058543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer